Metastatic Breast Cancer clinical trials

Explore recruiting metastatic breast cancer clinical trials.

Recruiting metastatic breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention

Portugal

Therapeutic use (Phase IV) EU CTIS Study details

Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally advanced or metastatic breast cancer previously treated with a CDK4/6 inhibitor in combination with hormonal therapy: a multicenter, phase II trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)

Poland, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

Basket study for oligo-metastatic breast cancer - ANISE

Netherlands, France, Italy, Spain, Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blinded, placebo-controlled, multicenter, phase II/III efficacy and safety study of oral TherO2-01S22 as add-on therapy on top of first line anti-HER2 targeted treatment of patients with Metastatic Breast Cancer TherO2-01S22 in HER2-positive breast cancer: TherO2-MBC Study

France

Phase II and Phase III (Integrated) EU CTIS Study details

Metastatic Breast Cancer trials by city

Metastatic Breast Cancer in Toronto Metastatic Breast Cancer in Vancouver Metastatic Breast Cancer in Montreal Metastatic Breast Cancer in Calgary Metastatic Breast Cancer in Edmonton Metastatic Breast Cancer in Ottawa Metastatic Breast Cancer in Winnipeg Metastatic Breast Cancer in Quebec City Metastatic Breast Cancer in Hamilton Metastatic Breast Cancer in Kitchener Metastatic Breast Cancer in London Metastatic Breast Cancer in Halifax Metastatic Breast Cancer in New York Metastatic Breast Cancer in Los Angeles Metastatic Breast Cancer in Chicago Metastatic Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease